Makers of life-supporting and -sustaining devices – and other critical products used during the ongoing COVID-19 public health emergency – must let the US Food and Drug Administration know if they’re expecting a disruption in manufacturing or supply.
That’s according to a new immediately-in-effect guidance document from the agency that explains how manufacturers should comply with Sec. 506J of the Federal Food, Drug and Cosmetic Act.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?